The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAs the healthcare sector's earnings season approaches, attention turns to Abbott Laboratories as it prepares to release its second-quarter results. According to reports, the company is expected to achieve growth across its Diagnostics, Medical Devices, and Established Pharmaceutical Products (EPD) segments. However, the Nutrition segment remains a potential drag that could weigh on the company's overall financial performance during this period.
This anticipation comes at a time of intense competition in the medical device sector, with recent results from Intuitive Surgical (ISRG) showing strong growth in surgical volumes, bolstering positive expectations for the broader industry. Looking at historical performance, Abbott recorded 10.8% organic sales growth in its Medical Devices segment in Q1, driven by the success of technologies like FreeStyle Libre, per market data and prior financial filings.
Regarding market performance, ABT stock closed at $93.93 (close July 10, 2026), with the share price fluctuating between a day low of $93.47 and a high of $94.97. Investors are currently monitoring support levels near $93.40, awaiting fresh catalysts from the official earnings report which will define the stock's trajectory for the second half of the year.